Amneal Pharmaceuticals is to stake a claim in “one of the most compelling generic product markets in the United States today” by signing a 10-year licence and supply agreement with Jerome Stevens Pharmaceuticals (JSP) for levothyroxine sodium tablets, after the family-owned company opted against renewing its existing agreement with Lannett (see page 14).
Set to come into effect from 22 March next year, when the Lannett agreement expires, Amneal’s arrangement with JSP includes...





